卫光生物(002880) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was CNY 208,518,007.07, representing a 51.34% increase compared to CNY 137,783,337.47 in the same period last year[4] - Net profit attributable to shareholders was CNY 45,736,044.33, an increase of 80.54% from CNY 25,333,345.87 year-on-year[4] - Basic earnings per share rose to CNY 0.2017, up 80.57% from CNY 0.1117 in the same quarter last year[4] - Total operating revenue for Q1 2023 reached ¥208,518,007.07, a significant increase of 51.2% compared to ¥137,783,337.47 in Q1 2022[16] - Net profit for Q1 2023 was ¥45,625,876.61, representing a 80.9% increase from ¥25,205,287.60 in Q1 2022[17] - Earnings per share (EPS) for Q1 2023 was ¥0.2017, compared to ¥0.1117 in the same period last year, reflecting a 80.5% increase[18] - The total comprehensive income for Q1 2023 was ¥45,625,876.61, compared to ¥25,205,287.60 in Q1 2022, showing a strong growth trajectory[18] Cash Flow - The net cash flow from operating activities reached CNY 51,288,202.98, a significant improvement from a negative CNY 5,378,157.74 in the previous year, marking a 1,053.64% increase[4] - Cash inflow from operating activities totaled ¥258,633,808.51, an increase from ¥182,856,172.52 in Q1 2022[19] - The net cash flow from operating activities for Q1 2023 was ¥51,288,202.98, compared to a negative cash flow of ¥5,378,157.74 in the same period last year[20] - The net cash flow from investing activities was negative at ¥81,871,610.61, a decrease from the previous year's negative cash flow of ¥56,440,030.96[20] - The net cash flow from financing activities was positive at ¥47,169,380.45, down from ¥162,125,824.98 in Q1 2022[20] - The net increase in cash and cash equivalents for Q1 2023 was ¥16,585,972.82, compared to an increase of ¥100,307,636.28 in Q1 2022[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,656,276,378.90, a 3.13% increase from CNY 2,575,733,822.26 at the end of the previous year[4] - Total assets as of March 31, 2023, amounted to ¥2,656,276,378.90, up from ¥2,575,733,822.26 at the beginning of the year, indicating a growth of about 3.1%[14] - Total liabilities decreased from ¥229,755,503.63 to ¥211,557,179.25, a reduction of approximately 7.9%[14] - Total liabilities increased to ¥743,116,795.21 from ¥708,199,697.29, reflecting a growth of 4.9% year-over-year[17] - Total equity attributable to shareholders reached ¥1,886,545,110.45, up from ¥1,840,809,066.12, marking a growth of 2.5%[17] Operating Costs and Income - The company reported a 54.51% increase in operating costs, totaling CNY 121,477,101.04, primarily due to increased sales volume[6] - Operating costs amounted to ¥155,644,988.93, up 42.3% from ¥109,391,163.31 in the previous year, with operating costs per revenue decreasing[16] - Other income increased by 42.48% to CNY 2,634,046.04, mainly due to higher government subsidies received[7] - The company reported a significant increase in other income to ¥2,634,046.04 from ¥1,848,731.39, indicating improved financial performance[17] Shareholder Information - Total number of common shareholders at the end of the reporting period is 10,140[9] - The largest shareholder, Shenzhen Guangming District State-owned Assets Supervision and Administration Bureau, holds 65.25% of shares, totaling 147,987,000 shares[9] - The company has no preferred shareholders as of the reporting period[11] Research and Development - Research and development expenses were ¥10,819,588.91, slightly up from ¥10,460,066.69 in the previous year, indicating continued investment in innovation[16] Other Information - The company has initiated a share acquisition plan as of January 10, 2023, and a non-public stock issuance plan on March 30, 2023[11] - The first phase employee stock ownership plan holds 820,890 shares, representing a small portion of the total shares[10] - The company did not conduct an audit for the Q1 2023 report[21] - The report was presented by the board of directors on April 24, 2023[22]